

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FIRST NAMED INVENTOR APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. CONFIRMATION NO. Derek A. Pratt N-6636 9766 09/891,671 06/26/2001 **EXAMINER** 03/05/2004 STITES & HARBISON TRUONG, TAMTHOM NGO **424 CHURCH STREET** ART UNIT PAPER NUMBER **SUITE 1800** NASHVILLE, TN 37219 1624

DATE MAILED: 03/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)
•		09/891,671	PRATT ET AL.
Office Action Summary	Examiner	Art Unit	
•		Tamthom N. Truong	1624
 Period for	The MAILING DATE of this communication app	pears on the cover sheet wit	th the correspondence address
A SHO THE M - Extens after S - If the p - If NO p - Failure Any rej	RTENED STATUTORY PERIOD FOR REPLIALLING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.1 IX (6) MONTHS from the mailing date of this communication. eriod for reply specified above is less than thirty (30) days, a repliance for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statute ply received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a re ly within the statutory minimum of thirty will apply and will expire SIX (6) MONT e, cause the application to become ABA	ply be timely filed  (30) days will be considered timely.  HS from the mailing date of this communication.  ANDONED (35 U.S.C. § 133).
Status		•	
2a)□ 1 3)□ 5	Responsive to communication(s) filed on $02 F$ . This action is <b>FINAL</b> . 2b) This Since this application is in condition for allowal closed in accordance with the practice under $E$ .	s action is non-final.  nce except for formal matte	·
Dispositio	n of Claims		
4: 5)□ ( 6)⊠ ( 7)⊠ (	Claim(s) 32-42,44-48 and 51-63 is/are pending a) Of the above claim(s) 53-63 is/are withdray claim(s) is/are allowed. Claim(s) 32-42,48,51 and 52 is/are rejected. Claim(s) 44-47 is/are objected to. Claim(s) are subject to restriction and/o	vn from consideration.	
Applicatio	n Papers		
9) The specification is objected to by the Examiner.			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.		
	•	ammor. Note the attached	omoc / Galori of form 1 10 102.
_	der 35 U.S.C. § 119		
a)[ 	cknowledgment is made of a claim for foreign  All b) Some * c) None of:  Certified copies of the priority documents  Certified copies of the priority documents  Copies of the certified copies of the priority documents  application from the International Bureau  e the attached detailed Office action for a list	s have been received. s have been received in Ap rity documents have been re u (PCT Rule 17.2(a)).	plication No eceived in this National Stage
Attachment(s	s) of References Cited (PTO-892)	A) 🗔 Intonite C	mmon//DTO 412)
2)  Notice o 3)  Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) tion Disclosure Statement(s) (PTO-1449 or PTO/SB/08) lo(s)/Mail Date 5.	Paper No(s)/	mmary (PTO-413) Mail Date ormal Patent Application (PTO-152) -

Application/Control Number: 09/891,671

Art Unit: 1624

## **DETAILED ACTION**

Applicant's amendment of 02-02-04 is acknowledged. The following response is presented.

Withdrawal of Finality: Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn. Also, a new reference is found which raises a new ground of rejection.

**Filing Date:** It's acknowledged the filing date of June 25, 2001 has been granted in the petition of January 31, 2002. However, the examiner does not have access to the system for fixing the filing date. Applicant is advised to contact the Office of Initial Patent Examination (OIPE).

Claims 53-63: These claims were not originally presented, and are drawn to different methods of use. That is, claims 53-61 are drawn to "a method of stabilizing a monomer", and claims 62 and 63 are drawn to "a method of inhibiting the oxidation of a polymer".

Therefore, they are not considered as per 37 C.F.R. 1.142(b) and MPEP § 821.03. The restriction was presented to show that the new claims are drawn to different inventions.

Thus claims 53-63 are still held withdrawn from consideration.

With claims 43, 49, and 50 cancelled, only claims 32-42, 44-48, 51, and 52 remain for consideration.

Application/Control Number: 09/891,671

Art Unit: 1624

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 1. Claims 32-35, 37, 40, 42, 48, 51 and 52 are rejected under 35 U.S.C. 103(a) as being unpatentable over **Henrie**, **II et. al.** (US 5,521,192 cited on IDS) as applied to claims above, and further in view of **Treybig et. al.** (US 4,871,848).

On column 6, **Henrie et. al.** disclose a salt of *2,4-diamino-5-hydroxy-pyrimidine*. The free form *2,4-diamino-5-hydroxy-pyrimidine* reads on formula 4 in claim 32 when R<sub>1</sub> is amino; R<sub>2</sub> is hydrogen, and R<sub>3</sub> is an electron-donating substituent. It also reads on the compound recited in claims 35, 37 as R<sub>1</sub> and R<sub>3</sub> represent amino groups. Likewise, said free form reads on the formulae in claims 40 and 42 as R<sub>2</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> represent hydrogen atoms. The teaching of Henrie et. al. differs from the instant claims by not relating the disclosed compound to a method of reducing the rate of oxidation in a petroleum composition.

Such a difference can be remedied by the teaching of **Treybig et. al.** On column 3, Treybig et. al. disclose several aromatic nitrogen-containing heterocycles, including pyrimidines (as a class) that are used in a composition to inhibit corrosion in oil or gas well. Then, on columns 24-25, Treybig et. al. suggest that "the corrosion inhibitors of this invention are

Application/Control Number: 09/891,671

Art Unit: 1624

suitable for the protection of metal alloys against corrosion due to corrosive fluids produced in oil and gas well formation..." Clearly Treybig et. al. recognize that oil and gas can be oxidized and produce corrosive fluids, and that pyrimidines (as a class) can reduce the oxidation in oil and gas which in turn inhibits the corrosion of oil or gas well. Furthermore, it is understood in the chemical art that corrosion is often caused by oxidation.

Therefore, with the teaching of Treybig et. al., one of the ordinary skill in the art would have been motivated to apply the pyrimidine compound of Henrie et. al. in a method of reducing the rate of oxidation in a petroleum composition as recited in claims 32-34, 48, 51, and 52 as well as those recited in claims 35, 37, 40, and 42.

Thus, at the time of the invention, it would have been obvious to one skill in the art to develop the claimed method in view of the combined teachings above.

2. Claims 32, 35, 36, 38, 39, and 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over **LaMattina** (US 4,554,276 – cited on IDS) as applied to claims above, and further in view of **Treybig et. al.** (US'848).

On column 10 of US'276, in Example 7, LaMattina discloses a compound of 2-amino-5-hydroxy-4-methylpyrimidine which reads on the formula of claims 32, 35, 36 as either R<sub>1</sub> or R<sub>2</sub> is hydrogen while the other is alkyl, and R<sub>3</sub> is amino. It also reads on formula 7 of claims 38, 39 and 41 as either R<sub>1</sub> or R<sub>2</sub> is hydrogen while the other is methyl, and R<sub>4</sub> is hydrogen. The teaching of LaMattina differs from the instant claims by not relating said compound to a method of reducing the rate of oxidation in a petroleum composition.

Again, said difference can be remedied by the teaching of Treybig et. al. That is, pyrimidines as a class can be used in a composition to inhibit corrosion of oil or gas well, which suggests reducing the oxidation in the oil or gas composition.

Thus, at time of the invention, it would have been obvious for one skilled in the art to apply the compound of LaMattina in a methods claimed herein in view of the teaching of Treybig et. al.

## Claim Objections

3. Claims 44-47 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Those claims recite species that are not disclosed in Henrie et. al. or LaMattina, and the teaching of Treybig et. al. is too broad for a prima facie case of obviousness on the method using species in those claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M-T ( $\sim 10$  am  $\sim 8:30$  pm) starting from February  $22^{nd}$ , 2004.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached at 571-272-0674. If you are unable to reach Dr. Shah within a 24 hour period, please contact James O. Wilson, Acting SPE of 1624, at 571-272-0661.

The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

T. Truong

\*\*\*

February 25, 2004

**JAMES O. WILSON** 

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600